China has reportedly approved the world's first brain-computer chip for commercial use, beating Tesla CEO Elon Musk's Neuralink to the market. According to a report by the New York Post, the coin-sized device, called NEO, has cleared clinical trials and is set to enter mass production for the state-run health system.
NEO Chip: A Less Invasive Approach
Version one of the chip is optimized to improve the nervous system of patients suffering from spinal cord injuries and paralysis. Unlike Neuralink's implants, which penetrate brain tissue with electrodes, NEO uses a less invasive approach. Its sensors are placed on the brain's protective membrane, the dura mater, reducing surgical risks while still capturing brain signals.
Elon Musk's 'Jesus-Level Technologies'
Elon Musk has long touted the potential of brain implants, calling them 'Jesus-level technologies' for their ability to restore sight and reverse paralysis. Neuralink promises users the ability to perform routine tasks using thought control, such as typing or moving a mouse. However, with China's approval of NEO, Beijing has taken the lead in commercializing brain-computer interfaces.
Key Differences Between China's NEO and Elon Musk's Neuralink
- Design: NEO is a coin-sized implant that sits between the skull and brain, with eight sensors pressed against the dura mater. It is less invasive. Neuralink's N1 implant places tiny electrodes directly into the brain's cortex, penetrating tissue to detect electrical signals. It is more invasive.
- Purpose (Initial Use): NEO focuses on patients with spinal cord injuries and paralysis, helping restore movement via robotic gloves and assistive devices. Neuralink aims to enable thought-controlled typing, cursor movement, and eventually restore sight and motor functions.
- Clinical Trials: NEO was tested on 36 patients with promising results and no major safety issues. Neuralink's human trials began in 2024, currently tested on a smaller group of about 20 patients, still under evaluation.
- Regulatory Status: NEO has commercial approval from China's National Medical Products Administration and is entering mass production for the state-run health system. Neuralink has no commercial approval yet and is still undergoing U.S. FDA regulatory review.
- Approach to Invasiveness: NEO is minimally invasive, reducing surgical risks. Neuralink is highly invasive, requiring direct cortical penetration for higher-resolution data.
- Market Position: NEO is the first brain-computer interface cleared for commercial sale worldwide. Neuralink is still in the experimental stage, positioned as a future 'Jesus-level technology' by Musk.
Promise and Peril
As per the New York Post report, advocates see brain chips as enablers of digital telepathy and telekinesis, while also treating mental conditions like depression, epilepsy, stroke, and Parkinson's disease. However, experts warn that the technology could expose sensitive neural data to hackers. 'Brain implants may sound dystopian, but they are a promising part of neuroscience research,' said Griffith University's Dr. David Tuffley, adding that they could theoretically allow access to patients' thoughts and memories.
Venture capitalist Scott Phoenix told a TED talk in April: 'We're on the cusp of the next major transition, the merger of humans and AI. Someone you work with will get it first… eventually, you won't be able to hold out.' This vision is shared by OpenAI CEO Sam Altman and investor Peter Thiel, who see brain-computer interfaces as the next frontier of human-machine integration.
